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The directed synthesis of organometallic cage molecules for
the assembly of molecular nano-objects is a topical area of
chemical research.[1] By combining the “molecular clip”
strategy developed by Stang[2] with the “molecular paneling”
strategy pioneered by Fujita,[3] we recently synthesized
trigonal-prismatic cage molecules in which six (h6-arene)ru-
thenium or (h5-pentamethylcyclopentadienyl)rhodium units
are held together by two trigonal 2,4,6-tris(pyridin-4-yl)-1,3,5-
triazine (tpt) panels and three dichloro[4] or oxalato[5] bridges.
We have now extended this principle to construct the larger
cationic hexanuclear metalloprism [Ru6(p-iPrC6H4Me)6(tpt)2-
(dhbq)3]
6+ (16+), which incorporates p-cymene ruthenium
building blocks and is bridged by 2,5-dihydroxy-1,4-benzo-
quinonato (dhbq) ligands and connected by two tpt subunits
(Scheme 1).
The hexametallic cation 16+ was prepared from the
dinuclear complex [Ru2(p-iPrC6H4Me)2(dhbq)Cl2]
[6] and tpt
in the presence of AgO3SCF3. The cationic complex was
isolated and characterized as its triflate salt 1-(OSO2CF3)6 in
75% yield. The assembly of 16+ can also be achieved in the
presence of [Pd(acac)2] or [Pt(acac)2] (acac= acetylaceto-
nato) to give the “complex-in-a-complex” cations
[(acac)2Pd1]6+ and [(acac)2Pt1]6+ without affecting the
overall yield (Scheme 2). Cations [(acac)2Pd1]6+ and
[(acac)2Pt1]6+ were both isolated as their triflate salts.
The formation of [(acac)2Pd1]6+ and [(acac)2Pt1]6+ can
easily be monitored by 1H NMR spectroscopy and their
molecular structure established by one-dimensional 1H
ROESY experiments. The CH and Me signals of the
acetylacetato ligands in the 1H NMR spectra of
[(acac)2Pd1]6+ and [(acac)2Pt1]6+ are shifted upfield by
about 1.7 ppm relative to the free complexes in [D6]acetone
(see the Supporting Information). One-dimensional 1H
ROESY experiments confirmed the molecular structure of
cations [(acac)2Pd1]6+ and [(acac)2Pt1]6+. Thus, intense
cross-peaks are observed between the protons of the encap-
sulated complex (Hacac andMeacac) and the protons of the cage
molecule (Htpt, Hcym, Hdhbq) in close proximity (see Supporting
Information).
The molecular structure of [(acac)2Pt1]6+ was confirmed
by single-crystal X-ray structure analysis of [(acac)2Pt1]-
(O3SCF3)6 (Figure 1).
[7] The structure shows the [Pt(acac)2]
complex to be held between the triazine units of the tpt
ligands. It is clear from the van der Waals representation of
the “complex-in-a-complex” cation that the Pt(acac)2 com-
plex is indeed encapsulated in 16+; the separation between
platinum and triazine-centroid being 3.4 ?. The {Ru2-
Scheme 1. Synthesis of [1](O3SCF3)6.
Scheme 2. Synthesis of [(acac)2Pd1](O3SCF3)6 and [(acac)2Pt1]-
(O3SCF3)6.
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(dhbq)2+} clips are tilted out of the plane of the tpt subunits by
as much as 148 to accommodate the [Pt(acac)2] complex
within the cavity of 16+.
To examine the stability of the cage in solution, we
recorded the 1H NMR spectra in D2O at elevated temper-
atures (Figure 2). The 1H NMR spectra of 16+,
[(acac)2Pd1]6+, and [(acac)2Pt1]6+ in D2O show no signal
changes, thereby indicating the stability of the cage. The
[M(acac)2] complexes are only (partially) released after a
prolonged period, with the palladium complex being released
to a greater extent.
Given the well-established anti-cancer activity of plati-
num compounds[8] and the promising anti-cancer potential of
ruthenium complexes,[9] several of which are currently under-
going clinical evaluation,[10] we studied the cytotoxicity of the
two “complex-in-a-complex” cations [(acac)2Pd1]6+ and
[(acac)2Pt1]6+ with respect to the empty hexaruthenium
cage 1 and the free acetylacetonato complexes [Pd(acac)2]
and [Pt(acac)2] against A2780 human ovarian cancer cells.
One of the main challenges in cancer chemotherapy is to
develop drugs that are selective towards cancer cells in order
to reduce the general toxicity and consequently the side
effects of the compound. One such targeting method involves
using large carrier compounds which release the drug once
inside a cancer cell, since large compounds selectively
accumulate in cancer cells owing to the “enhanced perme-
ability and retention effect”.[11] Herein, 16+ represents the
carrier compound and its high charge also potentially
facilitates uptake in cancer cells.[12] We found that cisplatin
can also be encapsulated within 16+, but it rapidly leaches
from the hydrophobic pocket in water. However, the more
hydrophobic complexes [M(acac)2] (M=Pd, Pt) are strongly
immobilized within 16+, while being almost insoluble in water
in their free form under ambient conditions. Indeed, the
cytotoxicity data of the compounds described herein is in
complete correlation with their observed solubility/stability
properties (Table 1). The free [M(acac)2] complexes, which
are virtually insoluble in water (the palladium species being
slightly more soluble), show no cytotoxic effects on the A2780
human ovarian cancer cells. However, while the cage complex
16+ is moderately cytotoxic, both “complex-in-a-complex”
species [(acac)2M1]6+ are more active, with the platinum-
containing species being about twice as active as the empty
cage and the palladium entrapped species being more than
one order of magnitude more cytotoxic; indeed, the IC50 value
of 1 mm for [(acac)2Pd1]6+ is extremely low in comparison to
other platinum and ruthenium complexes. The higher cyto-
toxicity of [(acac)2Pd1]6+ with respect to that of
[(acac)2Pt1]6+ may suggest that the palladium complex is
more easily released from the hexaruthenium cage 16+ than
the platinum complex. Once inside a cell, the hexaruthenium
cage may open and release the [M(acac)2] complex to the
biological target. Amore detailed study of this mode of action
is in progress.
A large number of polynuclear metal complexes have
been evaluated as putative anticancer agents.[13] In general,
these complexes are based on metal centers connected
through bridging ligands or metal centers connected to
macromolecular supports. However, to our knowledge, the
“Trojan horse” strategy described herein represents the first
example in which a relatively hydrophobic complex encapsu-
lated within a hydrophobic pocket of a metal-containing host
functions in a synergic fashion by accelerated release inside a
cancer cell.
Experimental Section
All organic solvents were saturated with nitrogen prior to use.
[Pd(acac)2], [Pt(acac)2], and 2,5-dihydroxy-1,4-benzoquinone
(dhbqH2) were purchased from Fluka. 2,4,6-Tris(pyridin-4-yl)-1,3,5-
triazine (tpt)[14] and [Ru2(p-iPrC6H4Me)2(dhbq)Cl2]
[6] were prepared
according to published methods. NMR spectra were recorded with a
Varian 200 MHz or Bruker 400 MHz spectrometer. IR spectra were
Figure 1. Molecular structure of [(acac)2Pt1]6+; side view and top
view.
Figure 2. 1H NMR spectra of [(acac)2Pd1]6+ (D2O, 200 MHz) at
elevated temperature (& acac, f dhbq, c tpt, * p-iPrC6H4Me).









[a] IC50 : drug concentration necessary for 50% inhibition of cell viability.
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recorded with a Perkin–Elmer 1720X FT-IR spectrometer (4000–
400 cm1). Microanalyses were performed by the Laboratory of
Pharmaceutical Chemistry, University of Geneva (Switzerland).
1-(O3SCF3)6: A mixture of [Ru2(p-iPrC6H4Me)2(dhbq)Cl2]
(60 mg, 0.09 mmol) and AgO3SCF3 (46 mg, 0.18 mmol) in MeOH
(20 mL) was stirred at room temperature for 2 h, then filtered. The
ligand tpt (18.4 mg, 0.06 mmol) was then added to the red filtrate and
the mixture stirred at room temperature for 48 h. The solvent was
then removed under vacuum. The dark residue was taken up in
CH2Cl2 (20 mL) and, after filtration, the solution was concentrated
(3 mL) and diethyl ether added to precipitate a red solid. Yield: 75 mg
(75%). 1H NMR (400 MHz, [D6]acetone): d= 8.75 (dd,
3JH,H=
5.36 Hz, 4JH,H= 1.56 Hz, 12H; Ha), 8.68 (dd,
3JH,H= 5.36 Hz,
4JH,H=
1.56 Hz 12H; Hb), 6.24 (d,
3JH,H= 6.32 Hz, 12H; Har), 6.03 (d,
3JH,H=
6.32 Hz, 12H; Har), 5.87 (s, 6H; Hq), 3.00 (sept,
3JH,H= 6.92 Hz, 6H;
CH), 2.28 (s, 18H; CH3), 1.41 ppm (d,
3JH,H= 6.92 Hz, 36H; CH3);
13C{1H} NMR (100 MHz, [D6]acetone): d= 170.04, 154.86, 144.66,
125.15, 123.26, 120.24, 104.42, 102.16, 99.53, 84.19, 82.72, 31.57, 21.98,
17.63 ppm; IR: n˜= 1635(s), 1524(s), 1377(m), 1259(s), 1161(m),
1031(m), 639(s) cm1. C,H,N analysis (%) calcd for
C120H114F18N12O30S6Ru6 (3345.0): C 43.09, H 3.44, N 5.02; found: C
42.96, H 3.33, N 4.86.
[(acac)2M1](O3SCF3)6: A mixture of [Ru2(p-iPrC6H4Me)2-
(dhbq)Cl2] (60 mg, 0.09 mmol) and AgO3SCF3 (47 mg, 0.18 mmol)
in MeOH (20 mL) was stirred for 2 h, then filtered. [M(acac)2] (M=
Pd, 10 mg, 0.03 mmol; M=Pt, 13 mg, 0.03 mmol) and tpt (18 mg,
0.06 mmol) were added to the red filtrate to give a red solution. The
mixture was stirred at room temperature for 15 h and the solvent
removed under vacuum. The dark residue was taken up in CH2Cl2
(20 mL) and, after filtration, the solution was concentrated (3 mL)
and diethyl ether added to precipitate a red solid.
[(acac)2Pd1](O3SCF3)6: Yield: 75 mg (69%). 1H NMR
(400 MHz, [D6]acetone): d= 8.68 (dd,
3JH,H= 6.04 Hz, 24H; py),
6.23 (d, 3JH,H= 5.60 Hz, 12H; Arp-cym), 6.02 (d,
3JH,H= 5.60 Hz, 12H;
Arp-cym), 5.88 (s, 6H), 3.68 (s, 2H; CH), 2.95 (sept,
3JH,H= 6.80 Hz, 6H;
CH), 2.26 (s, 18H; CH3), 1.40 (d,
3JH,H= 6.80 Hz, 36H; CH3),
0.44 ppm (s, 12H, CH3);
13C{1H} NMR (100 MHz, [D6]acetone): d=
184.06, 182.87, 170.03, 158.24, 143.37, 124.16, 122.15, 121.38, 105.32,
103.52, 101.09, 84.66, 82.34, 32.14, 24.28, 22.56, 18.22 ppm; IR: n˜=
1688(s), 1526(s), 1439(s), 1223(s), 1092(s), 1032(m), 981(m), 908(s),
896(s), 846(m) cm1. C,H,N analysis (%) calcd for
C130H128F18N12O34PdRu6S6 (3649.7): C 42.78, H 3.54, N 4.61; found:
C 42.53, H 3.17, N 4.53.
[(acac)2Pt1](O3SCF3)6: Yield: 70 mg (62%). 1H NMR
(400 MHz, [D6]acetone): d= 8.66 (s, 24H; py), 6.22 (d,
3JH,H=
6.40 Hz, 12H; Arp-cym), 6.02 (d,
3JH,H= 6.40 Hz, 12H; Arp-cym), 5.90
(s, 6H), 3.77 (s, 2H; CH), 2.98 (sept, 3JH,H= 7.00 Hz, 6H; CH), 2.26 (s,
18H; CH3), 1.38 (d,
3JH,H= 7.00 Hz, 36H; CH3), 0.30 ppm (s, 12H;
CH3);
13C{1H} NMR (100 MHz, [D6]acetone): d= 184.94, 184.46,
170.53, 155.29, 145.66, 125.83, 124.08, 120.88, 105.12, 102.72, 100.17,
84.76, 83.32, 32.14, 24.46, 22.27, 18.31 ppm; IR: n˜= 1709(s), 1526(s),
1340(s), 1208(s), 1093(s), 1032(m), 831(s) cm1. C,H,N analysis (%)
calcd for C130H128F18N12O34PtRu6S6 (3738.3): C 41.77, H 3.45, N 4.50;
found: C 41.56, H 3.40, N 4.33.
Human A2780 ovarian carcinoma cells were obtained from the
European Centre of Cell Cultures (ECACC, Salisbury, UK) and
maintained in culture as described by the provider. The cells were
routinely grown in RPMI 1640 medium containing 10% foetal calf
serum (FCS) and antibiotics at 37 8C and 6% CO2. For the growth
inhibition tests, the cells were seeded in 96-well plates and grown for
24 h in complete medium. The complexes were diluted to the required
concentration and added to the cell culture for 72 h incubation.
Solutions of the compounds were applied by diluting a freshly
prepared stock solution of the corresponding compound in aqueous
RPMI medium (20 mm). The MTT test was performed in the last 2 h
without changing the culture medium. Following drug exposure, MTT
(Sigma) was added to the cells at a final concentration of 0.2 mgmL1
and incubated for 2 h, then the culture medium was aspirated and the
violet formazan precipitate dissolved in 0.1n HCl in 2-propanol. The
optical density was quantified at 540 nm using a multiwell plate
reader (iEMS Reader MF, Labsystems, US), and the percentage of
surviving cells was calculated from the ratio of absorbance of treated
to untreated cells. The IC50 values for the inhibition of cell growth
were determined by fitting the plot of the percentage of surviving cells
against the drug concentration using a sigmoidal function (Origin
v7.5).
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